Physician profile
James Doyle
NPI 1023674793
$1,281.32
in general payments reported to CMS, 2019-2025
28 companies · $999 in 2025
The $999 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $282 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.34 |
| Education | $381.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $213.50 | 2023-2025 | Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $121.62 | 2023-2025 | Iclusig |
| E.R. Squibb & Sons, L.L.C. | $108.55 | 2025 | Breyanzi |
| Seagen INC. | $98.00 | 2023 | |
| Pfizer INC. | $74.75 | 2025 | |
| Genzyme Corporation | $61.87 | 2025 | |
| Cycle Pharmaceuticals INC | $57.85 | 2025 | Phyrago |
| Celgene Corporation | $49.92 | 2025 | Breyanzi |
| Daiichi Sankyo INC. | $48.05 | 2025 | Enhertu |
| Avyxa Pharma, LLC | $39.15 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.13 | 2025 | Enhertu |
| Abbvie INC. | $34.95 | 2025 | |
| Springworks Therapeutics, INC. | $32.12 | 2025 | Ogsiveo |
| Glaxosmithkline, LLC. | $30.32 | 2025 | Blenrep, Ojjaara, Jemperli |
| Tersera Therapeutics LLC | $28.62 | 2025 | Zoladex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.08 | 2025 | Keytruda |
| Sun Pharmaceutical Industries INC. | $23.63 | 2025 | |
| Janssen Biotech, INC. | $23.38 | 2025 | Carvykti |
| Octapharma USA, INC. | $21.11 | 2025 | Octagam Immune Globulin (Human) |
| Sumitomo Pharma America, INC. | $20.57 | 2025 | Orgovyx |
| Array Biopharma INC | $19.53 | 2025 | Xalkori |
| Jazz Pharmaceuticals INC. | $19.01 | 2025 | |
| Pharmaand Gmbh | $17.00 | 2025 | Rubraca |
| Tolmar, INC. | $17.00 | 2025 | Rubraca, Eligard |
| Sobi, INC | $15.05 | 2025 | |
| Aveo Pharmaceuticals, INC. | $14.28 | 2025 | |
| Adc Therapeutics America, INC. | $14.14 | 2025 | |
| Servier Pharmaceuticals LLC | $14.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.